We conducted a single-center clinical trial involving 31 children and young adult patients with R/R B-ALL who were treated with humanized CD19-specific CAR-T cells(hCART19s)from May 2016 to September 2021. Here, CD19 is linked to acute lymphoblastic leukemia.